The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Trial updates from ASCO GI 2021
Mohamed E. Salem, MD, Levine Cancer Institute, Charlotte, NC, provides a summary of key data presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including an abstract evaluating the prognostic impact of molecular residual disease in colorectal cancer, as well as the findings from the FIGHT study (NCT03694522) in patients with gastric cancer. Dr Salem also highlights updates in the KEYNOTE-177 and Alliance A021501 studies, in colorectal and pancreatic cancer respectively. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
